Immunotherapy: Recurrent and/or metastatic head and neck cancer portends a poor prognosis with traditional treatments, but current immunotherapy with immune checkpoint inhibitors has the potential to improve these clinical outcomes. This review focuses on the major breakthroughs that have led to the current understanding of immunotherapy in head and neck cancer as well as the future direction of the field. Ultimately, this understanding will guide clinicians on the selection of patients with head and neck cancer and practical considerations before starting immunotherapy.
http://ift.tt/2uzxiwD
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
REVIEW ARTICLES Human tail: A benign condition hidden out of social stigma and shame in young adult – A case report and review p. 1 Pramo...
-
Abstract Background Preliminary evidence suggests osteoarthritis is a risk factor for cognitive decline. One potential reason is 87% of ...
-
Publication date: Available online 2 August 2017 Source: Neuroscience Research Author(s): Mamoru Takeda, Masanori Nasu, Takuya Kanazawa, ...
-
Abstract Objectives Innovative mental health care delivery models have been proposed as a method to address disparities in access and uti...
-
Immune response profile of primary tumour, sentinel and non-sentinel axillary lymph nodes related to metastasis in breast cancer: an immunoh...
-
Abstract Background In order to gain insight into the early effects drawn by JAK inhibitors on intra-joint JAK/STAT-dependent signaling,...
-
Abstract Introduction We report a pure distraction injury of the upper thoracic spine and uncontrolled hyperthermia without an infectious...
-
Publication date: 1 November 2017 Source: Talanta, Volume 174 Author(s): Yan Xiong, Jiayi Wu, Qing Wang, Jing Xu, Shenwen Fang, Jie Chen, ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου